G. T. Budd

1.5k total citations
20 papers, 1.1k citations indexed

About

G. T. Budd is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, G. T. Budd has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in G. T. Budd's work include Cancer Treatment and Pharmacology (6 papers), Cancer Cells and Metastasis (4 papers) and Cancer Genomics and Diagnostics (4 papers). G. T. Budd is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Cancer Cells and Metastasis (4 papers) and Cancer Genomics and Diagnostics (4 papers). G. T. Budd collaborates with scholars based in United States, Australia and Canada. G. T. Budd's co-authors include Ronald M. Bukowski, Sucheta Kulkarni, Pratima Karnik, Stephen E. Jones, Kathleen I. Pritchard, EE Lower, John K. Erban, Donald Richards, Leslie Rodgers Laufman and Beth Overmoyer and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

G. T. Budd

20 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. T. Budd United States 11 710 346 327 278 192 20 1.1k
Zhenzhou Shen China 20 689 1.0× 574 1.7× 204 0.6× 551 2.0× 202 1.1× 54 1.5k
Ermelinda De Maio Italy 16 533 0.8× 284 0.8× 217 0.7× 425 1.5× 235 1.2× 30 1.1k
Laura García‐Estévez Spain 20 1.1k 1.5× 649 1.9× 201 0.6× 438 1.6× 506 2.6× 68 1.7k
Chung-Tsen Hsueh United States 19 556 0.8× 200 0.6× 82 0.3× 416 1.5× 305 1.6× 55 1.2k
Shona Nag India 13 720 1.0× 217 0.6× 75 0.2× 228 0.8× 228 1.2× 34 1.0k
R. Theriault United States 13 970 1.4× 439 1.3× 101 0.3× 264 0.9× 162 0.8× 25 1.3k
Michael E. Menefee United States 15 610 0.9× 181 0.5× 159 0.5× 484 1.7× 209 1.1× 45 1.3k
Flavia Morales-Vásquez Mexico 12 652 0.9× 416 1.2× 83 0.3× 402 1.4× 198 1.0× 28 1.3k
Alejandra Perez United States 12 842 1.2× 588 1.7× 126 0.4× 493 1.8× 611 3.2× 30 1.6k
Jin-Song Lu China 16 492 0.7× 465 1.3× 223 0.7× 499 1.8× 93 0.5× 20 1.1k

Countries citing papers authored by G. T. Budd

Since Specialization
Citations

This map shows the geographic impact of G. T. Budd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. T. Budd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. T. Budd more than expected).

Fields of papers citing papers by G. T. Budd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. T. Budd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. T. Budd. The network helps show where G. T. Budd may publish in the future.

Co-authorship network of co-authors of G. T. Budd

This figure shows the co-authorship network connecting the top 25 collaborators of G. T. Budd. A scholar is included among the top collaborators of G. T. Budd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. T. Budd. G. T. Budd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Cook, Thomas B., et al.. (2011). Abstract 13988: Cardioprotective Effect of Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Treated with Trastuzumab: A Follow-Up Study of Heart Failure and Cardiac Function Over 12 Months. Circulation. 124. 2 indexed citations
3.
Wesolowski, Robert, Mohammed S. Orloff, Erinn Downs‐Kelly, et al.. (2010). Effect of kinesins on taxane resistance.. Journal of Clinical Oncology. 28(15_suppl). 10545–10545. 1 indexed citations
4.
Doyle, Gerald V., G. T. Budd, Madeline Repollet, et al.. (2008). Detection of Bcl-2 and apoptosis in circulating tumor cells during treatment of metastatic breast cancer. Journal of Clinical Oncology. 26(15_suppl). 11016–11016. 2 indexed citations
5.
Jones, Stephen E., John K. Erban, Beth Overmoyer, et al.. (2005). Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer. Journal of Clinical Oncology. 23(24). 5542–5551. 419 indexed citations
6.
Cristofanilli, Massimo, G. T. Budd, Matthew J. Ellis, et al.. (2005). Presence of circulating tumor cells (CTC) in metastatic breast cancer (MBC) predicts rapid progression and poor prognosis. Journal of Clinical Oncology. 23(16_suppl). 524–524. 8 indexed citations
7.
Budd, G. T., Massimo Cristofanilli, Matthew J. Ellis, et al.. (2005). Monitoring circulating tumor cells (CTC) in non-measurable metastatic breast cancer (MBC). Journal of Clinical Oncology. 23(16_suppl). 503–503. 10 indexed citations
8.
Hayes, Daniel F., G. T. Budd, A. Stopeck, et al.. (2004). Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): A prospective, multi-institutional tria. Journal of Clinical Oncology. 22(14_suppl). 509–509. 2 indexed citations
9.
Olencki, Thomas, et al.. (2002). A Phase I Trial of Weekly Gemcitabine and Subcutaneous Interferon Alpha in Patients with Refractory Renal Cell Carcinoma. Investigational New Drugs. 20(3). 305–310. 9 indexed citations
10.
Vaziri, S. A., Lisa M. Krumroy, Paul Elson, et al.. (2001). Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.. PubMed. 7(7). 1937–45. 51 indexed citations
11.
Stoner, G D, William L. Hayton, Kenneth K. Chan, et al.. (2000). Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis.. PubMed. 6(1). 78–89. 82 indexed citations
12.
Stoner, G D, G. T. Budd, Laura A. Kresty, et al.. (1999). Sulindac Sulfone Induced Regression of Rectal Polyps in Patients with Familial Adenomatous Polyposis. Advances in experimental medicine and biology. 470. 45–53. 77 indexed citations
13.
Bukowski, Ronald M., Patricia Rayman, Luis Moltó, et al.. (1999). Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma.. PubMed. 5(10). 2780–9. 34 indexed citations
14.
Taylor, Charles W., William S. Dalton, Silvana Martino, et al.. (1998). Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.. Journal of Clinical Oncology. 16(3). 994–999. 142 indexed citations
15.
Bukowski, Ronald M., Patricia Rayman, Robert G. Uzzo, et al.. (1998). Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.. PubMed. 4(10). 2337–47. 49 indexed citations
16.
17.
Bukowski, Ronald M., James H. Finke, Michael J. Caulfield, et al.. (1994). Phase I Trial of Cisplatin, WR-2721, and the Murine Monoclonal Antibody R24 in Patients with Metastatic Melanoma. Journal of Immunotherapy. 15(4). 273–282. 12 indexed citations
18.
Karnik, Pratima, et al.. (1994). Estrogen receptor mutations in tamoxifen-resistant breast cancer.. PubMed. 54(2). 349–53. 152 indexed citations
19.
Budd, G. T., Thomas R. Fleming, Ronald M. Bukowski, et al.. (1987). 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study.. Journal of Clinical Oncology. 5(2). 272–277. 70 indexed citations
20.
Montie, James E., et al.. (1984). Initial observations and problems with in vitro predictive assay in genitourinary malignancies. Urology. 23(4). 370–373. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhenzhou Shen Breakdown of academic impact, for papers by Ermelinda De Maio Breakdown of academic impact, for papers by Laura García‐Estévez Breakdown of academic impact, for papers by Chung-Tsen Hsueh Breakdown of academic impact, for papers by Shona Nag Breakdown of academic impact, for papers by R. Theriault Breakdown of academic impact, for papers by Michael E. Menefee Breakdown of academic impact, for papers by Flavia Morales-Vásquez Breakdown of academic impact, for papers by Alejandra Perez Breakdown of academic impact, for papers by Jin-Song Lu
Rankless by CCL
2026